The global gene therapy market reached a value of US$ 3.77 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.5 Billion by 2027 exhibiting a CAGR of 15.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Gene therapy is a technique for preventing disease progression by modifying the expression of mutated genes or altering the biological properties of living cells for therapeutic use. It improves the ability of the body to fight against a wide range of diseases, such as cancer, diabetes, hemophilia, cystic fibrosis, heart disease, and acquired immunodeficiency syndrome (AIDS). Nowadays, a wide variety of gene therapy products are available worldwide, which include viral vectors, bacterial vectors, plasmid deoxyribonucleic acid (DNA), human gene-editing technology, and patient-derived cellular gene therapy.

Gene Therapy Market Trends:
The growing prevalence of inherited diseases and acquired disorders, in confluence with easy access to healthcare facilities, represents one of the key factors catalyzing the demand for gene therapy to improve the quality of life of patients. Moreover, the rising cases of genetic disorders, such as muscular dystrophy and cystic fibrosis, in children and young adults are bolstering the market growth. In line with this, the increasing geriatric population, which is more susceptible to develop infectious diseases on account of inappropriate gene activity, is contributing to the market growth. Apart from this, the development of new gene therapy that offers a safer, non-addictive alternative to opioids in treating a broad range of chronic pain conditions, such as lower back pain and rare neuropathic pain disorders, is favoring the market growth. In addition, a large variety of therapeutic genes are under investigation, including tumor suppressor, anti-angiogenesis, inflammatory cytokine, and micro ribonucleic acid (RNA) genes. These genes can assist in treating cancer, leukemia, severe combined immune deficiency, and blindness caused by retinitis pigmentosa, which is anticipated to stimulate the growth of the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global gene therapy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on gene type, vector type, delivery method and application.

Breakup by Gene Type:

Antigen
Cytokine
Tumor Suppressor
Suicide Gene
Deficiency
Growth Factors
Receptors
Others

Breakup by Vector Type:

Viral Vector
Adenoviruses
Lentiviruses
Retroviruses
Adeno-Associated Virus
Herpes Simplex Virus
Poxvirus
Vaccinia Virus
Others
Non-Viral Techniques
Naked and Plasmid Vectors
Gene Gun
Electroporation
Lipofection
Others

Breakup by Delivery Method:

In-Vivo Gene Therapy
Ex-Vivo Gene Therapy

Breakup by Application:

Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Disease
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V. and Voyager Therapeutics Inc. Key Questions Answered in This Report:
How has the global gene therapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global gene therapy market?
What are the key regional markets?
What is the breakup of the market based on the gene type?
What is the breakup of the market based on the vector type?
What is the breakup of the market based on the delivery method?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global gene therapy market and who are the key players?
What is the degree of competition in the industry?